MEDIA ADVISORY -- Ohio State Cancer Experts Available To Provide Perspective On Research Presented At Annual ASCO Meeting

June 02, 2011

COLUMBUS, Ohio – Cancer researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) are available for outside comment on research presented during the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) June 3-7 in Chicago.

During the meeting, press briefings will be held to discuss research in developmental therapeutics, cancer as a chronic disease, women's cancers and responding to the global cancer crisis.

Experimental Therapeutics
The OSUCCC-James is one of only seven NCI-funded programs in the country conducting both Phase I and Phase II clinical trials. Two experimental agents designed and developed at the OSUCCC – James are now in clinical trials testing.

  • Dr. Michael Caligiuri, director of Ohio State's Comprehensive Cancer Center; CEO of The James Cancer Hospital and president of the Association of American Cancer Institutes. His research focuses on natural killer cell biology and the molecular biology of acute myeloid leukemia.

  • Dr. Michael Grever, co-leads the OSUCCC – James Experimental Therapeutics program. He specializes in hematologic malignancies including, particularly chronic lymphocytic leukemia (CLL) and hairy cell leukemia.

  • Dr. Miguel Villalona-Calero, director of medical oncology. He specializes in experimental therapeutics for solid tumors, particularly lung cancer

  • Dr. John Byrd, director of the division of hematology specializing in experimental therapeutics for hematologic malignancies, including chronic lymphocytic leukemia (CLL) [or just CLL].

  • Dr. Tanios Bekaii-Saab, specializes in experimental agents for gastrointestinal malignancies.

    Global Cancer Crisis

    • Dr. Michael Caligiuri, director of Ohio State's Comprehensive Cancer Center; CEO of The James Cancer Hospital and president of the Association of American Cancer Institutes.. He can discuss cancer research collaborations with OSUCCC – James in China.

    • Dr. Don Benson, hematologist specializing in B-cell lymphoid malignancies including multiple myeloma, lymphoma and bone marrow transplant. He can discuss cancer research collaborations with OSUCCC – James and Israel, France and Europe.

    • Cancer as a Chronic Disease

      • Dr. Steven Clinton, director of the prostate and genitourinary oncology specializing in experimental therapeutics and prostate cancer.

      • Dr. Charles Shapiro, director of breast medical oncology specializing in novel therapies and side effects of treatment for breast cancer.

      • Dr. John Byrd, director of the division of hematology specializing in experimental therapeutics for hematologic malignancies, including chronic lymphocytic leukemia.

      Women's Cancer

      • Dr. Charles Shapiro, director of breast medical oncology specializing in novel therapies and side effects of treatment for breast cancer.

      Melanoma

      • Dr. Kari Kendra, medical oncologist specializing in breast cancer and melanoma. She can provide commentary for important melanoma research to be presented during the plenary session on Sunday, June 5.

      The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (cancer.osu.edu) is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top cancer hospitals in the nation, The James is the 205-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC – James is one of only seven centers in the country funded by the NCI to conduct both phase I and phase II clinical trials.

      # # #

      Contact: Eileen Scahill or Marti Leitch, Medical Center Public Affairs and Media Relations, 614-293-3737, or Eileen.Scahill@osumc.edu or Marti.Leitch@osumc.edu

Contact Media Staff

Amanda Harper

Director of Media Relations


614-685-5420 (direct)


614-293-3737 (main)


Amanda.Harper2@osumc.edu


Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.

 

If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

Chitosan-Coated, Chemotherapy-Packed Nanoparticles May Target Cancer Stem Cells

Nanoparticles packed with a clinically used chemotherapy drug and coated with an oligosaccharide derived from the carapace of crustaceans might effectively target and kill cancer stem-like cells...

Pelotonia 2015 – Getting Us Even Closer to a Cancer-Free World

Mile by mile, Pelotonia riders, virtual riders and thousands of volunteers are helping us get even closer to a cancer-free world, and every single dollar raised goes directly to cancer research at the...

Patients with Rare Lymphoma Find New Treatment Hope at The James

Patients with a rare, aggressive lymphoma caused by the Epstein Barr virus are finding new hope thanks to a treatment study at The James, where lymphoma research experts are looking for -- and...